The Bottom Line Brand-name and compounded tirzepatide deliver the same active ingredient through different regulatory pathways
Dispose of residual solutions according to institutional chemical hygiene rules
The protein-first approach works with or without medication
over seven years for semaglutide) limits exposure, the reproducible semaglutide signal highlights the need for individualized GLP-1 therapy and prospective risk stratification
The decision to prescribe semaglutide GLP-1 is made on an individual basis, often recommended for obese individuals with a BMI of 30 or higher, or those who are overweight (with a BMI of 27 or higher) and have at least one weight-related health condition
Key symptoms include persistent fatigue, paraesthesia (pins and needles) in hands or feet, numbness, difficulty walking or balance problems, memory difficulties, mood changes, and pallor